MIRA Pharmaceuticals & MIRALOGX Entered into an Exclusive Licensing Agreement for Ketamir-2
Shots:
- The agreement gives MIRA the exclusive rights to develop and market Ketamir-2 in the U.S., Canada, & Mexico, furthermore, as part of the deal, MIRALOGX has extended a $3 million line of credit to support the early stages of Ketamir-2 development
- The pre-clinical studies of Ketamir-2 showed superior bioavailability & clinically desirable gastrointestinal absorption profile vs ketamine. The drug will possibly eliminate common side effects such as sedation, addiction, dissociative symptoms, & cardiovascular concerns
- Ketamir-2 (Oral Ketamine Analog) is an investigational compound for treatment-resistant depression (TRD) & major depressive disorder with suicidal ideation (MDSI)
Ref: MIRA Pharmaceuticals | Image: MIRA Pharmaceuticals
Related News:- GSK Signs a Five Years Collaboration with Lyell to Develop Technologies Improving Cell Therapies for Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
